Recording of the June 28, 2023 Webinar on Ritlecitinib (Litfulo)

Link to the June 28, 2023 Webinar

On Jun 23, 2023 the US Food and Drug Administration approved Ritlecitinib (Litfulo) for the treatment of severe alopecia areata. This marks the second drug approved for severe forms of alopecia areata and comes just 12 months after the first drug (baricitinib) was FDA approved.

Ritlecitinib (now to be marketed as Litfulo) is approved for individuals 12 and over with severe alopecia. Similar to baricitinib, the drug does not help everyone but does help about 25 %-30% of patients achieve really good regrowth after six months of using the drug.

Similar to baricitinib, many patients do not respond completely to the medication - for reasons that are not entirely clear. The drug will be needed lifelong for most patients.

On Wednesday June 28, 2023, Dr. Donovan hosted a public webinar discussing ritlecitinib in more depth. He reviewed how well the drug works, the potential side effects, the unknown issues that still exist with the drug and review how Ritlecitinib compares to baricitinib. This is a recording of the complete webinar.